Madrigal Pharmaceuticals Completes Enrollment Of Clinical Outcomes Study Of Resmetirom In Patients With Compensated NASH/MASH Cirrhosis
Portfolio Pulse from Benzinga Newsdesk
Madrigal Pharmaceuticals has completed enrollment for its MAESTRO-NASH OUTCOMES study, which evaluates resmetirom for treating compensated NASH cirrhosis. Positive results could lead to the first approved medication for this condition and support full approval for noncirrhotic NASH.
October 21, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Madrigal Pharmaceuticals has completed enrollment for its MAESTRO-NASH OUTCOMES study on resmetirom. Positive results could lead to regulatory approval for treating compensated NASH cirrhosis, potentially making resmetirom the first approved medication for this condition.
The completion of enrollment in the MAESTRO-NASH OUTCOMES study is a significant milestone for Madrigal Pharmaceuticals. If the results are positive, it could lead to the first approved treatment for compensated NASH cirrhosis, which would be a major breakthrough in the field. This potential approval could significantly impact Madrigal's market position and stock price positively.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100